To detect individuals with primary adult-type lactose malabsorption, LCT genotyping (C/T−13910 polymorphism) was performed [12 (link)]. VACUETTE® K3EDTA tubes (2 mL) (Greiner Bio-One International GmbH, Kremsmünster, Austria) were drawn from patients for genomic DNA extraction on a MagNA Pure Compact Instrument (Roche Diagnostics, Rotkreuz, Switzerland). Real-time PCR with specific fluorescent labelled hybridization probes, followed by a melting curve analysis (LCT T-13910C ToolSet™ (Roche Diagnostics)), was established on a LightCycler® 2.0 Instrument (Roche Diagnostics).
A fructose breath test protocol was established to detect patients with fructose malabsorption. Gas chromatography was employed to measure the H2 and CH4 concentration using a QuinTron Model DP Plus MicroLyzer™ (QuinTron, Milwaukee, WI, USA). After determining baseline breath H2/CH4 concentrations, fructose was given in a dose of 25 g dissolved in 200 mL of water. The end-expiratory breath H2/CH4 concentrations were measured at 15, 30, 45, 60, 75, 90, and 120 minutes after fructose ingestion. Patients were classified with fructose malabsorption, if a H2 and/or CH4 increase >20 ppm above baseline concentrations was observed [11 (link), 12 (link), 20 (link)].
A fructose breath test protocol was established to detect patients with fructose malabsorption. Gas chromatography was employed to measure the H2 and CH4 concentration using a QuinTron Model DP Plus MicroLyzer™ (QuinTron, Milwaukee, WI, USA). After determining baseline breath H2/CH4 concentrations, fructose was given in a dose of 25 g dissolved in 200 mL of water. The end-expiratory breath H2/CH4 concentrations were measured at 15, 30, 45, 60, 75, 90, and 120 minutes after fructose ingestion. Patients were classified with fructose malabsorption, if a H2 and/or CH4 increase >20 ppm above baseline concentrations was observed [11 (link), 12 (link), 20 (link)].
Free full text: Click here
